Acquired FGFR2V564F gatekeeper mutations have been identified in patients with intrahepatic cholangiocarcinomas harboring FGFR2–BICC1, FGFR2–OPTN, or FGFR2–ZMYM4 fusions.151. Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.